Determinants of healthcare utilization and costs in COPD patients: first longitudinal results from the German COPD cohort COSYCONET

References

• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–2128. doi:10.1016/S0140-6736(12)61728-023245604
   PubMed Web of Science ®Google Scholar
• Geldmacher H, Biller H, Herbst A, et al. [The prevalence of chronic obstructive pulmonary disease (COPD) in Germany. Results of the BOLD study]. Dtsch Med Wochenschr. 2008;133(50):2609–2614.19052996
   PubMed Web of Science ®Google Scholar
• Soriano JB, Abajobir AA, Abate KH, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691–706. doi:10.1016/S2213-2600(17)30234-528822787
   PubMed Web of Science ®Google Scholar
• Mathers CD, Loncar D, Samet J. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. doi:10.1371/journal.pmed.003044217132052
   PubMed Web of Science ®Google Scholar
• Wacker ME, Hunger M, Karrasch S, et al. Health-related quality of life and chronic obstructive pulmonary disease in early stages - longitudinal results from the population-based KORA cohort in a working age population. BMC Pulm Med. 2014;14:134. doi:10.1186/1471-2466-14-13425107380
   PubMed Web of Science ®Google Scholar
• Wacker ME, Jorres RA, Karch A, et al. Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities. BMC Pulm Med. 2016;16(1):70. doi:10.1186/s12890-016-0276-327160582
   PubMed Web of Science ®Google Scholar
• Foo J, Landis SH, Maskell J, et al. Continuing to confront COPD international patient survey: economic impact of COPD in 12 countries. PLoS One. 2016;11(4):e0152618. doi:10.1371/journal.pone.015261827092775
   PubMed Web of Science ®Google Scholar
• Blanchette CM, Gross NJ, Altman P. Rising costs of COPD and the potential for maintenance therapy to slow the trend. Am Health Drug Benefits. 2014;7(2):98–106.24991394
   PubMedGoogle Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 2017 Report; 2017 Available from http://www.goldcopd.org/. Accessed June 18, 2019.
   Google Scholar
• van der Schans S, Goossens LM, Boland MR, et al. Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: methodological Considerations and Recommendations. PharmacoEconomics. 2017;35(1):43–63. doi:10.1007/s40273-016-0448-2
   PubMed Web of Science ®Google Scholar
• Fletcher MJ, Upton J, Taylor-Fishwick J, et al. COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population. BMC Public Health. 2011;11:612. doi:10.1186/1471-2458-11-61221806798
   PubMed Web of Science ®Google Scholar
• Wacker ME, Jorres RA, Schulz H, et al. Direct and indirect costs of COPD and its comorbidities: results from the German COSYCONET study. Respir Med. 2016;111:39–46. doi:10.1016/j.rmed.2015.12.00126725462
   PubMed Web of Science ®Google Scholar
• Karch A, Vogelmeier C, Welte T, et al. The German COPD cohort COSYCONET: aims, methods and descriptive analysis of the study population at baseline. Respir Med. 2016;114:27–37. doi:10.1016/j.rmed.2016.03.00827109808
   PubMed Web of Science ®Google Scholar
• Icks A, Dittrich A, Brune M, et al. Agreement found between self-reported and health insurance data on physician visits comparing different recall lengths. J Clin Epidemiol. 2017;82:167–172. doi:10.1016/j.jclinepi.2016.10.00927825891
   PubMed Web of Science ®Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DD Assignment 2010. Oslo: WHOCC; 2009.
   Google Scholar
• Bock JO, Brettschneider C, Seidl H, et al. [Calculation of standardised unit costs from a societal perspective for health economic evaluation]. Gesundheitswesen. 2015;77(1):53–61.25025287
   PubMed Web of Science ®Google Scholar
• Research Institute of the AOK. 2017 Available from: http://wido.de/forschung-projekte/arzneimittel/. Accessed June 18, 2019.
   Google Scholar
• Jones PW, Quirk FH, Baveystock CM, Littlejohns P; The St. George’s Respiratory Questionnaire. A self-complete measure of health status for chronic airflow limitation. Am Rev Respir Dis. 1992;145(6):1321–1327. doi:10.1186/s12890-016-0276-31595997
   PubMed Web of Science ®Google Scholar
• Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324–1343. doi:10.1183/09031936.0021371122743675
   PubMed Web of Science ®Google Scholar
• Karl FM, Holle R, Bals R, et al. Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients. Respir Res. 2017;18(1):60. doi:10.1186/s12931-017-0543-828416015
   PubMed Web of Science ®Google Scholar
• Jones PW, Brusselle G, Dal Negro RW, et al. Properties of the COPD assessment test in a cross-sectional European study. Eur Respir J. 2011;38(1):29–35. doi:10.1183/09031936.0017721021565915
   PubMed Web of Science ®Google Scholar
• Fletcher CM, Clifton M, Fairbairn AS, et al. Standardised questionnaire on repsiratory symptoms: a statement prepared and approved by the MRC Committee on the Aetiology of Chronic Bronchitis (MRC breathlessness score). BMJ. 1960;(2):1662.
   Google Scholar
• Putcha N, Puhan MA, Drummond MB, et al. A simplified score to quantify comorbidity in COPD. PLoS One. 2014;9(12):e114438. doi:10.1371/journal.pone.011443825514500
   PubMed Web of Science ®Google Scholar
• Wacker ME, Kitzing K, Jörres RA, et al. The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohort. Int J Chron Obstruct Pulmon Dis. 2017;12:3437. doi:10.2147/COPD.S15088729270005
   PubMed Web of Science ®Google Scholar
• Jansson SA, Backman H, Stenling A, Lindberg A, Ronmark E, Lundback B. Health economic costs of COPD in Sweden by disease severity–has it changed during a ten years period? Respir Med. 2013;107(12):1931–1938. doi:10.1016/j.rmed.2013.07.01223910072
   PubMed Web of Science ®Google Scholar
• Menn P, Heinrich J, Huber RM, et al. Direct medical costs of COPD–an excess cost approach based on two population-based studies. Respir Med. 2012;106(4):540–548. doi:10.1016/j.rmed.2011.10.01322100535
   PubMed Web of Science ®Google Scholar
• Lee J, Lee JH, Kim JA, Rhee CK. Trend of cost and utilization of COPD medication in Korea. Int J Chron Obstruct Pulmon Dis. 2017;12:27–33. doi:10.2147/COPD.S15088728031708
   PubMed Web of Science ®Google Scholar
• Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160(6):1856–1861. doi:10.1164/ajrccm.160.6.990211510588597
   PubMed Web of Science ®Google Scholar
• Jo YS, Kim YH, Lee JY, et al. Impact of BMI on exacerbation and medical care expenses in subjects with mild to moderate airflow obstruction. Int J Chron Obstruct Pulmon Dis. 2018;13:2261–2269. doi:10.2147/COPD.S16300030100716
   PubMed Web of Science ®Google Scholar